Litigation Details for Hoffmann-La Roche Inc. v. Airis Pharma Private Limited (S.D.N.Y. 2017)
✉ Email this page to a colleague
Hoffmann-La Roche Inc. v. Airis Pharma Private Limited (S.D.N.Y. 2017)
| Docket | ⤷ Subscribe | Date Filed | 2017-10-13 |
| Court | District Court, S.D. New York | Date Terminated | 2018-07-09 |
| Cause | 35:271 Patent Infringement | Assigned To | Katherine Bolan Forrest |
| Jury Demand | None | Referred To | |
| Parties | AIRIS PHARMA PRIVATE LIMITED | ||
| Patents | 8,889,109; 9,642,911 | ||
| Attorneys | Ryan Neil Hagglund | ||
| Firms | Blank Rome LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Hoffmann-La Roche Inc. v. Airis Pharma Private Limited
The small molecule drug covered by the patents cited in this case is ⤷ Subscribe .
Details for Hoffmann-La Roche Inc. v. Airis Pharma Private Limited (S.D.N.Y. 2017)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2017-10-13 | 1 | the ‘911 patent”). The Patented Drug is also protected by Plaintiffs’ U.S. Patent No. 8,889,109 (“the ‘… ‘109 patent”). Collectively, the ‘911 and ‘109 patents are referred to herein as the “Patents-in-Suit…claimed in a patent or the use of which is claimed in a patent before the expiration of such patent.” 28. …Oral Solution (the “Patented Drug”) prior to the expiration of Plaintiffs’ U.S. Patent No. 9,642,911 (“…exclusive licensee of the patents identified herein and commercializes the Patented Drug. 4. Upon information | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
